NDA 219455 · Fresenius Medcl Care
Cienby
Trisodium Citrate · Extracorporeal
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Oct 19, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
33
3 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CIENBY · TRISODIUM CITRATE 40GM/1000ML (1500ML) · SOLUTION, EXTRACORPOREAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trisodium" as an intervention, any sponsor and status, largest first.
- ACTIV-2: A Study for Outpatients With COVID-19Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04518410 · 4,044 participants · Start Aug 19, 2020 · Primary completion Apr 7, 2022
Drug: bamlanivimab 7000mg; BRII-196+BRII-198 and 19 more · For: Coronavirus; Covid19
Sites: Anniston, Alabama; Athens, Alabama; Birmingham, Alabama · 252 sites in all
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and RwandaPivotal-lookingCompleted
Victoria Biomedical Research InstituteAcademic, hospital or other
NCT07408297 · 1,919 participants · Start May 18, 2022 · Primary completion Jun 27, 2024
Drug: Janssen Ad26COVS1; Pfizer-BioNTech vaccine COVID-19 vaccine and 1 more · For: COVID -19; SARS CoV 2 Infection
Sites: Kisumu, Kenya
- Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney InjuryPivotal-lookingNot yet recruiting
Jianfeng XieAcademic, hospital or other
NCT07518303 · 1,162 participants (planned) · Start Jun 10, 2026 · Primary completion Jun 10, 2028
Drug: Citrate anticoagulation; Nafamostat Mesylate · For: Sepsis; Acute Kidney Injury; Continuous Renal Replacement Therapy (CRRT)
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04889209 · 867 participants · Start May 28, 2021 · Primary completion Jun 16, 2023
Drug: Ad26.COV2.S; BNT162b2 and 4 more · For: COVID-19
Sites: Decatur, Georgia; Baltimore, Maryland; New York, New York · 10 sites in all
Bachir TaouliAcademic, hospital or other
NCT01600105 · 276 participants · Start Oct 2010 · Primary completion Jul 31, 2017
Drug: Perfusion MRI · For: Chronic Liver Disease
Sites: New York, New York
- Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00296855 · 261 participants · Start Feb 2006
Drug: Vasovist (BAY86-5283, MS-325) · For: Peripheral Vascular Diseases
Sites: Buenos Aires, Argentina; Lornas de Zamora, Argentina; Sankt Pölten, Austria · 26 sites in all
- Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous HemofiltrationPivotal-lookingCompleted
Onze Lieve Vrouwe GasthuisAcademic, hospital or other
NCT00286273 · 215 participants · Start Mar 2003 · Primary completion Jan 2008
Drug: trisodium citrate; nadroparin · For: Kidney Failure, Acute
Sites: Amsterdam, Netherlands
- Comparative Effectiveness of 30%TSC and Heparin Lock Solution in Hemodialysis CathetersPivotal-lookingCompleted
Catholic University of PelotasAcademic, hospital or other
NCT02563041 · 179 participants · Start Jul 2012 · Primary completion Jul 2014
Drug: 30% TSC; Heparin · For: Catheter Related Infection
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of intra-nasal nitrilotriacetic acid trisodium salt in lowering elevated calcium cations and improving olfactory dysfunction in COVID-19 patients.
Abdelazim MH, Abdelazim AH, Ismaiel WF, et al. · Eur Arch Otorhinolaryngol 2022 · Randomized Controlled Trial
- Detection of hepatic metastasis: manganese- and ferucarbotran-enhanced MR imaging.
Choi JY, Kim MJ, Kim JH, et al. · Eur J Radiol 2006 · Controlled Clinical Trial, Research Support, Non-U.S. Gov't
- Effects of a Blend of Trisodium Citrate, Creatine Monohydrate, Leucine, and Blueberry Extract on Training-Induced Changes in Leg Extension Strength, Endurance, and Muscle Size.
Roberts TD, Arnett JE, Ortega DG, et al. · J Diet Suppl 2025 · Randomized Controlled Trial
- MRI with mangafodipir trisodium in the detection of pancreatic tumours: comparison with helical CT.
Rieber A, Tomczak R, Nüssle K, et al. · Br J Radiol 2000 · Clinical Trial, Clinical Trial, Phase III
- Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: a prospective study.
Schneider M, Thomas K, Liefeldt L, et al. · Clin Nephrol 2007 · Clinical Trial
- Measurement of the Concentration of Citrate in Human Biofluids in Patients Undergoing Continuous Renal Replacement Therapy Using Regional Citrate Anticoagulation: Application of a Two-Step Enzymatic Assay.
Anstey CM, Russell FD · Blood Purif 2021 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Fresenius Medcl Care
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.